Morpholine

Morpholine

SCHEMBL6137775

C1COCCN1.Cc1ccncc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CYP2C9 P11712 2/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
ADRB2 P07550 1/20 0.44
NCF1 P14598 1/20 0.44
PLD1 Q13393 1/20 0.44
ADRB1 P08588 1/20 0.39
APEX1 P27695 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
HTR2C P28335 2/20 0.34
HTR2B P41595 2/20 0.34
HTR1D P28221 1/20 0.34
HTR2A P28223 1/20 0.34
HTR1E P28566 1/20 0.34
HTR7 P34969 1/20 0.34
HTR3A P46098 1/20 0.34
HTR5A P47898 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL4622954 0.79 MEN1 (0.61) MEN1KMT2ACYP2C9KDM4EGAA
Morpholine SCHEMBL23361658 0.79 CYP2C9 (0.44) MEN1KMT2ACYP2C9KDM4EGAA
Morpholine SCHEMBL28199219 0.79 ADRB2 (0.40) MEN1KMT2ACYP2C9KDM4EGAA
Toluene SCHEMBL3946837 0.78 LMNA (0.50) MEN1KMT2ACYP2C9KDM4EGAA
3-Methylpyridine SCHEMBL28247355 0.77 CHRNB2 (0.41) MEN1KMT2ACYP2C9KDM4EGAA
Fluoride SCHEMBL30330168 0.76
Morpholine SCHEMBL7697197 0.75 MEN1 (0.44) MEN1KMT2ACYP2C9KDM4EGAA
Morpholine SCHEMBL4270671 0.75 ACHE (0.54) MEN1KMT2ACYP2C9KDM4EGAA
SCHEMBL1310594 0.74 LMNA (0.50) MEN1KMT2AKDM4EGAAALDH1A1
SCHEMBL12062 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109251742-A A kind of visco-elastic surfactant acid corrosion inhibiter and preparation method thereof 中国石油天然气集团有限公司 2019-01-22 CN claimed
CN-109251742-A A kind of visco-elastic surfactant acid corrosion inhibiter and preparation method thereof 中国石油天然气集团有限公司 2019-01-22 CN disclosed
US-20050085534-A1 Process for the preparation of citalopram RANBAXY LABORATORIES (IN) 2005-04-21 US disclosed
EP-1370545-A4 PROCESS FOR THE PREPARATION OF CITALOPRAM RANBAXY LAB LTD (IN) 2005-03-16 EP disclosed
EP-1370545-A1 PROCESS FOR THE PREPARATION OF CITALOPRAM Ranbaxy Laboratories, Limited (IN) 2003-12-17 EP disclosed
WO-2002072565-A1 PROCESS FOR THE PREPARATION OF CITALOPRAM RANBAXY LABORATORIES LIMITED (IN) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085534-A1 Process for the preparation of citalopram SLC6A4, SLC6A2, MAOA MEN1 1737/4885KMT2A 1653/4885CYP2C9 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.